SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

The pharmaceutical giant claims that Gutierrez Co. failed to properly design and build its manufacturing facility in Marlborough, Massachusetts.

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

Moderna stock hasn’t been a favorite of investors since demand for its coronavirus vaccine started to drop. But this biotech is showing the market that it has what it takes to produce multiple ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...